CG
RXRX icon

Caprock Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Caprock Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.5K Buy
+14,861
New +$49.5K ﹤0.01% 1219
2026
Q1 		– Sell
-13,026
Closed -$53.3K – 1275
2025
Q4 		$53.3K Buy
+13,026
New +$64.5K ﹤0.01% 1176

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Caprock Group's RXRX Position: Q2 2026 in Review

Caprock Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 14,861 shares worth $54.5K. The stake represents ﹤0.01% of the portfolio and ranks #1219 among its holdings. This is a return to the name: Caprock Group previously reported a position in RXRX as recently as Q4 2025.

Caprock Group first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Caprock Group held 14,861 shares of Recursion Pharmaceuticals worth $54.5K as of Q2 2026.
  • Recursion Pharmaceuticals was a new Caprock Group position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Caprock Group's portfolio in Q2 2026, its #1219 holding.
  • Caprock Group first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.